It's like an **AI-powered IBM Watson**, but focused entirely on discovering and personalizing cancer therapies.

Imagine **23andMe** or **Ancestry.com**, but instead of just genetic insights, they use AI to find and develop personalized cancer treatments for patients.

• Clinical Testing & Research Services: Provides tumor drug response testing, genomic profiling, and AI-driven patient-centric drug discovery research.
• Organ-Specific Disease Models: Develops 3D human tissue models that simulate disease states for testing anticancer agents.
• Biologics Formulation & Stability: Offers services for high-throughput identification of soluble protein formulations, protein stability analysis, and bacterial endotoxin management.
• Medical Fluid Waste Management & Cell Culture: Delivers the STREAMWAY System for automated disposal of infectious fluids and specialized media for ex vivo cancer cell growth.

The company described in the background information, Predictive Oncology Inc. (symbol: AGPU), primarily sells its products and and services to other companies and institutions.

Its major categories of customers include:

• Pharmaceutical and Biotechnology Companies: These customers leverage Predictive Oncology Inc.'s AI-driven drug discovery, preclinical testing models (via the zPREDICTA segment), protein formulation and stability services (from the Soluble segment), and specialized R&D services and cell culture media.
• Healthcare Facilities and Providers: Hospitals, surgical centers, and clinics utilize the company's clinical testing services (via the Helomics segment), genomic profiling tests, and the STREAMWAY System for automated fluid waste management (from the Skyline segment).
• Academic and Contract Research Organizations (CROs): These organizations engage with Predictive Oncology Inc. for contract research services, patient-centric drug discovery, and specialized analytical and testing services across various segments.

Christopher Miglino
Chief Executive Officer

Christopher Miglino was appointed Chief Executive Officer of Axe Compute on February 9, 2026. He was instrumental in structuring Axe Compute's digital asset treasury and facilitating the company's entry into the AI compute market. With over 25 years of experience in technology, fintech, media, and digital assets, Mr. Miglino is also the co-founder and former CEO of SRAX Inc. (NASDAQ: SRAX), a financial technology company he launched in March 2010, took public on the OTC market in 2012, and subsequently listed on NASDAQ in 2015. Prior to SRAX, he founded Centerlinq, an interactive kiosk system, and Conscious Enlightenment, a media company, both of which he successfully sold to NASDAQ-traded companies. In 2020, SRAX acquired LD Micro, a micro-cap specialist data company. He was also involved in the sale of SRAX's remaining interest in the SRAX MD asset for $8 million in 2020. In May 2024, DNA Holdings LLC entered into a merger agreement to acquire a majority stake in SRAX, with Mr. Miglino expected to lead the combined entity as CEO.

Josh Blacher
Chief Financial Officer

Josh Blacher serves as the Chief Financial Officer of Axe Compute, having been appointed interim CFO for its predecessor, Predictive Oncology, on September 30, 2023, and confirmed as CFO on October 14, 2025. He brings over two decades of financial leadership experience in the life sciences and biotech sectors, specializing in financial strategy, capital raising, and corporate development for both private and public companies. Mr. Blacher's previous roles include CFO positions at Galmed Pharmaceuticals (October 2014 – March 2017) and Therapix Biosciences (April 2017 – April 2018), and Chief Business Officer at InMed Pharmaceuticals (April 2018 – August 2019), where he was instrumental in the company's NASDAQ IPO. He has also held CFO roles at Rampart Bioscience and Excision BioTherapeutics. Since August 2019, he has been a Managing Partner at Columbus Circle Capital, and from September 2022, he has provided CFO services through Danforth Advisors.

Sara Turken
Senior VP & General Counsel

Sara Turken is the Senior Vice President and General Counsel at Axe Compute.

Lawrence DeLucas
Senior Vice President of Biologics

Lawrence DeLucas serves as the Senior Vice President of Biologics at Axe Compute.

Thomas McLaughlin
Chief Investment Officer

Thomas McLaughlin is the Chief Investment Officer. He was mentioned in the context of Predictive Oncology (now Axe Compute) earnings calls, discussing the company's investment strategy and deployment of assets, particularly concerning its digital asset treasury.

Intense Competition and Market Acceptance in the AI Compute Infrastructure Market

Dependence on the Aethir Decentralized Cloud GPU Network

Strategic Uncertainty and Transition of the Legacy AI-Driven Drug Discovery Business

Here are clear emerging threats for Predictive Oncology Inc. (AGPU):

• Advancements in AI from larger tech and pharmaceutical players: Predictive Oncology leverages AI for personalized cancer therapies and drug discovery. However, larger technology companies and major pharmaceutical firms are investing heavily in developing more powerful, comprehensive, and widely accessible AI platforms for oncology research, diagnostics, and drug development. If these entities deploy superior AI models with greater predictive accuracy, speed, or integrated functionality across the drug discovery and clinical trial continuum, they could significantly undermine the specialized AI offerings of Predictive Oncology’s Helomics and zPREDICTA segments. This parallels how larger, more integrated ecosystems disrupted specialized technologies in historical examples.
• Disruptive *in vitro* modeling technologies: The zPREDICTA segment focuses on developing organ-specific 3D disease models for testing anticancer agents. The rapid emergence and adoption of advanced *in vitro* technologies, such as "organ-on-a-chip" systems or more complex microphysiological systems, pose a significant threat. These newer models often offer enhanced physiological relevance, higher throughput capabilities, and potentially lower costs for drug screening, which could lead pharmaceutical companies to prefer them over zPREDICTA's current 3D reconstruction models.
• Evolution of surgical fluid waste management systems: The Skyline segment's STREAMWAY System provides an automated solution for surgical fluid waste. An emerging threat comes from the development of entirely new, potentially more cost-effective, or integrated systems for managing surgical fluids. This could include advanced robotic solutions that incorporate fluid handling, more sophisticated disposable systems offering comparable safety and efficiency at a lower capital expenditure, or shifts in surgical practices that minimize fluid waste, thereby reducing the demand for dedicated, wall-mounted systems like STREAMWAY.

Axe Compute Inc. (NASDAQ: AGPU), formerly known as Predictive Oncology Inc., operates in several market segments related to AI-driven drug discovery, biomedical research services, and more recently, AI compute infrastructure.

Addressable Markets for Axe Compute Inc. (AGPU)

The addressable markets for Axe Compute's main products and services are primarily global, with significant activity and growth often highlighted in North America and Asia-Pacific regions.

AI-Driven Drug Discovery and Related Services:

• AI-Powered Drug Discovery: The global AI-powered drug discovery market was valued at approximately USD 1.89 billion in 2024 and is projected to reach about USD 15.71 billion by 2032, expanding at a compound annual growth rate (CAGR) of 30.3%. Another estimate places the market at USD 2.35 billion in 2025, growing to USD 13.77 billion by 2033.
• Genomic Profiling and Testing (Helomics segment): The global genomic tests market size was valued at USD 18.24 billion in 2025 and is expected to reach USD 39.87 billion by 2033. The global precision genomic testing market, a related area, is projected to grow from USD 17.89 billion in 2025 to approximately USD 62.34 billion by 2034.
• 3D Cell Culture Models (zPREDICTA segment): The global 3D cell culture market was valued at about USD 2.98 billion in 2025 and is estimated to reach USD 8.30 billion by 2034, with North America holding a significant share (over 39.8% in 2025). Other projections indicate the market reaching USD 7.83 billion by 2035 from USD 2.61 billion in 2025.
• Protein Stability Analysis (Soluble segment): The global protein stability analysis market is valued at approximately USD 2.44 billion in 2025 and is expected to reach USD 5.23 billion by 2032. Another report estimates the market at USD 2.14 billion in 2025, growing to USD 4.33 billion by 2033.
• Bacterial Endotoxin Testing (Soluble segment): The global bacterial endotoxin testing market was valued at USD 1.38 billion in 2025 and is expected to attain around USD 2.77 billion by 2033. Another source states a market size of USD 1.26 billion in 2024, projected to reach USD 3.02 billion by 2034.
• Cancer Cell Culture Media (Skyline/TumorGenesis segment): The global cell culture media market size is valued at approximately USD 3.86 billion in 2025 and is expected to reach USD 7.72 billion by 2032. Another projection shows the market at USD 7.69 billion in 2025, reaching around USD 20.32 billion by 2034.

AI Compute Infrastructure and GPU Cloud Services (Newer Focus):

• AI Infrastructure: The global Artificial Intelligence (AI) infrastructure market is projected to reach USD 164.0 billion in 2025 and grow to USD 853.3 billion by 2034. Other estimates include a market size of USD 58.78 billion in 2025, growing to USD 497.98 billion by 2034, registering a CAGR of 26.60%. North America held 37.10% of this market in 2025. A significant portion of this market, particularly the hardware segment (63.26% in 2026), is driven by specialized chips like GPUs.

Axe Compute (NASDAQ: AGPU) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, primarily stemming from its strategic pivot into high-performance artificial intelligence (AI) infrastructure services, while continuing its existing AI-driven drug discovery operations. The company, formerly known as Predictive Oncology Inc., rebranded as Axe Compute Inc. on December 12, 2025, and began trading under the AGPU ticker, signaling a significant expansion of its business model.

The expected drivers of future revenue growth include:

1. Expansion into High-Performance Enterprise AI Infrastructure Services: A primary driver of future revenue is the company's strategic expansion into providing high-performance enterprise AI infrastructure. This new focus aims to meet the escalating global demand for predictable and scalable compute capacity required for various AI workloads. By diversifying its offerings beyond drug discovery, Axe Compute is tapping into a rapidly growing market for AI computing power.

2. Commercialization of the Aethir Decentralized GPU Network: Axe Compute plans to monetize access to the Aethir decentralized GPU network. The company intends to acquire rights to digital assets tied to compute capacity, starting with the Aethir network, to offer guaranteed GPU capacity, service-level agreements (SLAs), and corporate counterparty services to enterprises. This strategy establishes a new and direct revenue stream by providing essential computing resources to AI enterprises.

3. Addressing the AI Compute Supply Bottleneck for Enterprises: The company is positioning itself to alleviate the critical industry challenge of extended procurement timelines (40-52 weeks) for high-end GPU hardware and capacity constraints faced with centralized cloud providers. By offering a solution to this supply bottleneck through predictable and scalable decentralized compute resources, Axe Compute aims to attract and retain enterprise customers seeking immediate and reliable access to AI computing power.

4. Continued Revenue from AI-Driven Drug Discovery Operations: Despite its sharpened focus on AI compute infrastructure, Axe Compute will continue to operate its AI-driven drug discovery business. This segment, which leverages artificial intelligence for personalized cancer therapies, is expected to continue contributing to the company's overall revenue, building on its foundational expertise.

Capital Allocation Decisions for Axe Compute (AGPU)

Share Issuance

• In October 2025, the company closed private investment in public equity (PIPE) transactions totaling approximately $343.5 million. This included approximately $50.8 million in cash proceeds from the sale of shares and pre-funded warrants, and an in-kind contribution of ATH tokens with a notional value of approximately $292.7 million (discounted value of $173.3 million) in exchange for pre-funded warrants.
• Predictive Oncology Inc. (now Axe Compute Inc.) completed two reverse stock splits: a 1-for-20 split in April 2023 and a 1-for-15 split in September 2025, both primarily aimed at maintaining compliance with Nasdaq's minimum bid price requirement.
• Between January and February 2021, the company conducted registered direct offerings and a private placement, collectively raising approximately $29.1 million through the issuance of shares and associated warrants.

Inbound Investments

• Axe Compute received approximately $50.8 million in cash from a private placement and an in-kind contribution of ATH tokens valued at a discounted $173.3 million (notional $292.7 million) through PIPE transactions in October 2025 to support its digital asset treasury strategy.
• In July 2025, the company secured a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global, LP, providing a flexible funding source for its AI-driven drug discovery and ChemoFx expansion initiatives.

Outbound Investments

• In May 2025, Predictive Oncology Inc. completed the sale of its Skyline Medical assets to strategically streamline operations and sharpen its focus on AI-driven drug discovery capabilities.
• Axe Compute initiated a digital asset treasury strategy in December 2025, involving the acquisition of rights to digital assets (ATH tokens) tied to AI infrastructure, with plans to deploy these assets to generate revenue from enterprise clients.
• As of February 2026, Axe Compute is exploring strategic options for its Helomics business, indicating a potential divestiture of this segment to further focus on its core AI compute infrastructure.

Capital Expenditures

• The company's strategic shift in December 2025 involves acquiring rights to digital assets to secure GPU capacity and services for AI infrastructure, rather than making heavy physical infrastructure investments.
• In 2021 and 2022, cash flows used in investing activities were $10,607,536 and $475,697, respectively.
• For the nine months ended September 30, 2025, net cash used in operating activities from continuing operations was $5.9 million, averaging around $656,000 per month.